课件:慢性乙肝的规范化抗病毒治疗.ppt

  1. 1、本文档共62页,可阅读全部内容。
  2. 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
  3. 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  4. 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
课件:慢性乙肝的规范化抗病毒治疗.ppt

* 提问和回答 感谢您的倾听 * 2010年指南 一般适应证包括: (1) HBeAg阳性者,HBV DNA≥105拷贝/ml(相当于20 000 IU/ml);HBeAg阴性者,HBV DNA≥104拷贝/ml(相当于2000 IU/m1); (2) ALT≥2×ULN;如用IFN治疗,ALT应≤10×ULN,血清总胆红素应2×ULN; (3) ALT2×ULN,但肝组织学显示Knodell HAl≥4,或炎症坏死≥G2,或纤维化≥S2。 * 2010年版指南:对ALT大于ULN且年龄40岁者,也应考虑抗病毒治疗(III)。 (2) 对ALT持续正常但年龄较大者(40岁),应密切随访,最好进行肝活组织检查,如果肝组织学显示Knodell HAl≥4,或炎症坏死≥G2,或纤维化≥S2,应积极给予抗病毒治疗(II)。 (3) 动态观察发现有疾病进展的证据(如脾脏增大)者,建议行肝组织学检查,必要时给予抗病毒治疗(III)。 * * * * * * * ADV, adefovir; ETV, entecavir; HBV, hepatitis B virus; LdT, telbivudine; LAM, lamivudine; Pol, polymerase; TDF, tenofovir. * * * HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. ? Reactivation means a patient has a supposedly inactive disease that becomes reactive, so there is a reappearance of acute inflammatory liver disease in a person who is an inactive carrier. ? HBV reactivation has been well characterized as an increase in HBV DNA in a person who had previously undetectable or resolved HBV infection. This will be seen to varying degrees; some patients will have just elevated HBV DNA, whereas others will have elevated HBV DNA with elevated ALT, suggesting liver inflammation. Reactivation may occur spontaneously but also through immunosuppression or through chemotherapy. ? * * HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus. ? HBV reactivation may occur during or after chemotherapy. As an example, without prophylaxis, reactivation will occur in up to 85% of HBsAg-positive patients treated for non-Hodgkin lymphoma, with a 30% to 50% rate of death among these patients receiving steroid-containing chemotherapy. Reactivation can occur in both HBsAg-positive patients and those with anti-HBc antibody only. Individuals with anti-HBc antibody are those people who acquired HBV, did not develop immunity, and did not become a carrier. Therefore, clinicians who are going to be administering chemotherapy should be checking their patients for HBsAg, anti-HBs, and anti-HBc. ? * 14 These are the risk factors; not everyb

文档评论(0)

iuad + 关注
实名认证
内容提供者

该用户很懒,什么也没介绍

1亿VIP精品文档

相关文档